Skip to main content
GenFleet Therapeutics (Shanghai) Inc. logo

GenFleet Therapeutics (Shanghai) Inc. — Investor Relations & Filings

Ticker · 2595 HKEX Manufacturing
Open in API
Filings indexed 667 across all filing types
Latest filing 2026-04-28 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2595

About GenFleet Therapeutics (Shanghai) Inc.

http://www.genfleet.com

GenFleet Therapeutics is a clinical-stage biopharmaceutical company focused on developing first-in-class therapies in oncology and immunology. Established in 2017, the company employs a "Global New" strategy centered on source innovation, targeting novel biological pathways and indications that have not yet achieved clinical validation to build a differentiated, high-value pipeline. GenFleet has demonstrated particular expertise in developing RAS-pathway targeted therapies. The company integrates international clinical and commercial development routes, utilizing global strategic cooperation to facilitate the future entry of its products into worldwide markets.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT Statement on the Proprietary Intellectual Property Status of GFH276, a Pan RAS (ON) Inhibitor
Regulatory Filings Classification · 1% confidence The document is a voluntary corporate announcement on HKEX clarifying the company’s intellectual property status. It contains no financial results, no meeting materials, no board or management changes, no dividend or capital actions, and no formal legal proceeding update. It is a general regulatory announcement that does not fit any more specific category, so it is classified as a Regulatory Filing (fallback).
2026-04-28 English
FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON MONDAY, 11 MAY 2026
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal “Form of Proxy” for the company’s upcoming annual general meeting, used by shareholders to appoint proxies and submit voting instructions. This is classic proxy solicitation material, which falls under the category “Proxy Solicitation & Information Statement” (PSI). It is not the AGM presentation itself nor the meeting notice, but specifically the proxy form sent to shareholders.
2026-04-17 English
NOTICE OF THE 2025 ANNUAL GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal Notice of the 2025 Annual General Meeting of GenFleet Therapeutics (Shanghai) Inc., containing the date, venue, proposed ordinary and special resolutions, and detailed proxy voting instructions and procedures. It is not the actual annual report or AGM presentation materials, but rather the solicitation of shareholder votes and provision of meeting information, which aligns with the definition of a Proxy Solicitation & Information Statement (PSI).
2026-04-17 English
CIRCULAR OF THE 2025 ANNUAL GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a detailed shareholder circular issued by the Board in advance of the 2025 Annual General Meeting, containing the notice of meeting, explanatory statement, proposed resolutions (including approval of the annual report, audited accounts, directors’ remuneration, share mandates, corporate governance amendments, and auditor re-appointment), and proxy forms. These features match the definition of Proxy Solicitation & Information Statement (PSI): materials sent to shareholders to provide information and request votes for meetings.
2026-04-17 English
2025 Annual Report
Annual Report Classification · 1% confidence The document is clearly identified as the '2025 Annual Report' for GenFleet Therapeutics (Shanghai) Inc. It contains comprehensive sections including the Chairman's Statement, Management Discussion and Analysis, Corporate Governance, and audited financial statements (as indicated by the contents list and the presence of an Independent Auditor's Report section). It is a full-length annual report, not an announcement or a summary. FY 2025
2026-04-17 English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 March 2026
Regulatory Filings Classification · 1% confidence The document is a routine monthly return on movements in share capital and public float sufficiency filed with the Hong Kong Exchange under Listing Chapter 19B (Form FF301). It is not announcing an actual share issue, buyback, dividend, voting results, or board change, nor is it a full financial report or presentation. It is a regulatory listing rule compliance filing with no specific bespoke category, so it falls under the fallback “Regulatory Filings” category (RNS).
2026-04-09 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.